Flualprazolam: Report of an Outbreak of a New Psychoactive Substance in Adolescents
Flualprazolam: Report of an Outbreak of a New Psychoactive Substance in Adolescents
复制标题
DOI：
10.1542/peds.2019-2953
复制
发表时间：
2020-07-01
期刊：
影响因子：
8
通讯作者：
Gerona, Roy
中科院分区：
文献类型：
--
作者：
Blumenberg, Adam;Hughes, Adrienne;Gerona, Roy
一组青少年因氟普拉唑仑中毒而发生中枢神经系统抑制。氟阿普唑仑是一种未注册的苯二氮卓类药物，属于新型精神活性物质。自2014年以来，越来越多的设计师苯二氮卓类药物通过互联网和假药市场上市。2019年6月，俄勒冈州毒物中心发现一群氟阿普唑仑中毒患者。作为一种新出现的滥用药物，迄今为止，氟阿普唑仑的临床特征尚不清楚。在一个星期的时间里，6名青少年因非法获得假冒阿普唑仑而被送到当地急诊室，导致镇静。其他症状包括言语不清、意识模糊和轻度呼吸抑制。所有6名患者在摄入后6小时内症状均消退。从3名患者中获得血液和尿液样本以及片剂碎片。采用液相色谱-四极杆飞行时间质谱法对片剂和生物样品进行了分析，发现含有氟吡唑仑，不含其他药物或毒物。在这个病例系列中，我们在医学文献中增加了一个新出现的滥用药物的临床描述。氟阿普唑仑似乎与其他苯二氮卓类药物具有相同的临床特性。随着氟吡唑仑和其他NPS变得越来越普遍，医生必须了解它们的可用性和特征。镇静持续时间
A group of adolescents develop CNS depression due to intoxication with an NPS: flualprazolam. Flualprazolam is a nonregistered drug in the benzodiazepine family and constitutes a new psychoactive substance (NPS). Since 2014, a growing number of designer benzodiazepines have become available over the Internet and on the counterfeit drug market. In June 2019, a cluster of patients intoxicated with flualprazolam was identified by the Oregon Poison Center. As an emerging drug of abuse, the clinical characteristics of flualprazolam have been poorly characterized thus far. Over a one-week period, 6 teenagers presented to local emergency departments after ingesting illegally obtained counterfeit alprazolam, which led to sedation. Other symptoms included slurred speech, confusion, and mild respiratory depression. All 6 patients had resolution of their symptoms within 6 hours of ingestion. Blood and urine samples, as well as a tablet fragment, were obtained from 3 patients. The tablet and biological samples were analyzed by using liquid chromatography-quadrupole time-of-flight mass spectrometry and were found to contain the NPS flualprazolam without other drugs or intoxicants. With this case series, we add to the medical literature a clinical description of an emerging drug of abuse. Flualprazolam appears to share the clinical properties of other benzodiazepines. As flualprazolam and other NPSs become more common, physicians must be aware of their availability and characteristics. Sedation lasting